These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

223 related items for PubMed ID: 15322246

  • 21. Peptide/benzodiazepine hybrids as ligands of CCK(A) and CCK(B) receptors.
    Escherich A, Lutz J, Escrieut C, Fourmy D, van Neuren AS, Müller G, Schafferhans A, Klebe G, Moroder L.
    Biopolymers; ; 56(2):55-76. PubMed ID: 11592053
    [Abstract] [Full Text] [Related]

  • 22. Single amino acid substitution of serine82 to asparagine in first intracellular loop of human cholecystokinin (CCK)-B receptor confers full cyclic AMP responses to CCK and gastrin.
    Wu SV, Yang M, Avedian D, Birnbaumer M, Walsh JH.
    Mol Pharmacol; 1999 May; 55(5):795-803. PubMed ID: 10220557
    [Abstract] [Full Text] [Related]

  • 23. Conformational and molecular modeling studies of sulfated cholecystokinin-15.
    Giragossian C, Stone S, Papini AM, Moroder L, Mierke DF.
    Biochem Biophys Res Commun; 2002 May 10; 293(3):1053-9. PubMed ID: 12051766
    [Abstract] [Full Text] [Related]

  • 24. Fluorescence resonance energy transfer analysis of the antagonist- and partial agonist-occupied states of the cholecystokinin receptor.
    Harikumar KG, Miller LJ.
    J Biol Chem; 2005 May 13; 280(19):18631-5. PubMed ID: 15757907
    [Abstract] [Full Text] [Related]

  • 25. Insights into the binding and activation sites of the receptors for cholecystokinin and gastrin.
    Foucaud M, Archer-Lahlou E, Marco E, Tikhonova IG, Maigret B, Escrieut C, Langer I, Fourmy D.
    Regul Pept; 2008 Jan 10; 145(1-3):17-23. PubMed ID: 17961734
    [Abstract] [Full Text] [Related]

  • 26. Distinct molecular mechanisms for agonist peptide binding to types A and B cholecystokinin receptors demonstrated using fluorescence spectroscopy.
    Harikumar KG, Clain J, Pinon DI, Dong M, Miller LJ.
    J Biol Chem; 2005 Jan 14; 280(2):1044-50. PubMed ID: 15520004
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Differential spatial approximation between secretin and its receptor residues in active and inactive conformations demonstrated by photoaffinity labeling.
    Dong M, Hosohata K, Pinon DI, Muthukumaraswamy N, Miller LJ.
    Mol Endocrinol; 2006 Jul 14; 20(7):1688-98. PubMed ID: 16513792
    [Abstract] [Full Text] [Related]

  • 31. Demonstration of a specific site of covalent labeling of the human motilin receptor using a biologically active photolabile motilin analog.
    Matsuura B, Dong M, Coulie B, Pinon DI, Miller LJ.
    J Pharmacol Exp Ther; 2005 Jun 14; 313(3):1101-8. PubMed ID: 15677347
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Conformationally constrained CCK8 analogues obtained from a rationally designed peptide library as ligands for cholecystokinin type B receptor.
    De Luca S, Saviano M, Della Moglie R, Digilio G, Bracco C, Aloj L, Tarallo L, Pedone C, Morelli G.
    ChemMedChem; 2006 Sep 14; 1(9):997-1006. PubMed ID: 16915602
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Refinement of the structure of the ligand-occupied cholecystokinin receptor using a photolabile amino-terminal probe.
    Ding XQ, Dolu V, Hadac EM, Holicky EL, Pinon DI, Lybrand TP, Miller LJ.
    J Biol Chem; 2001 Feb 09; 276(6):4236-44. PubMed ID: 11050076
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. A single amino acid of the cholecystokinin-B/gastrin receptor determines specificity for non-peptide antagonists.
    Beinborn M, Lee YM, McBride EW, Quinn SM, Kopin AS.
    Nature; 1993 Mar 25; 362(6418):348-50. PubMed ID: 8455720
    [Abstract] [Full Text] [Related]

  • 38. Further evidence for a C-terminal structural motif in CCK2 receptor active peptide hormones.
    Stone SR, Giragossian C, Mierke DF, Jackson GE.
    Peptides; 2007 Nov 25; 28(11):2211-22. PubMed ID: 17950490
    [Abstract] [Full Text] [Related]

  • 39. Discovery of 1,5-benzodiazepines with peripheral cholecystokinin (CCK-A) receptor agonist activity. 1. Optimization of the agonist "trigger".
    Aquino CJ, Armour DR, Berman JM, Birkemo LS, Carr RA, Croom DK, Dezube M, Dougherty RW, Ervin GN, Grizzle MK, Head JE, Hirst GC, James MK, Johnson MF, Miller LJ, Queen KL, Rimele TJ, Smith DN, Sugg EE.
    J Med Chem; 1996 Jan 19; 39(2):562-9. PubMed ID: 8558528
    [Abstract] [Full Text] [Related]

  • 40. Molecular modelling of CCK-A receptors.
    Van Der Bent A, Ijzerman AP, Soudijn W.
    Drug Des Discov; 1994 Nov 19; 12(2):129-48. PubMed ID: 9116168
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.